Recent Updates — MDCX

Nasdaq notified Medicus Pharma Ltd. that it has regained compliance with the $1.00 minimum bid price requirement for continued listing, closing the matter as of October 23, 2026. This notice supersedes a delisting determination letter received on October 20, 2026, which had cited the company's failure to meet the requirement by the October 19 deadline and its ineligibility for an extension due to insufficient stockholders' equity. The company must continue to maintain compliance with Nasdaq's listing standards. Medicus Pharma Ltd. operates in the pharmaceutical industry.

Medicus Pharma Ltd. announced a fifty-to-one share consolidation of its common shares, effective October 12, 2026. The move aims to increase the bid price and restore compliance with Nasdaq Capital Market listing requirements. Shareholders will exchange every 50 pre-consolidation shares for one new share, with fractional shares rounded down and paid in cash. Proportionate adjustments apply to warrants and equity awards. Medicus Pharma Ltd. operates in the biopharmaceutical industry.

Medicus Pharma Ltd. mutually agreed with YA II PN, LTD. (Yorkville) to terminate the Standby Equity Purchase Agreement dated February 10, 2025, effective September 11, 2026. The agreement had authorized the issuance of up to $15.0 million in common shares; however, no borrowings, advance notices, or shares remained outstanding at termination. No fees are due by either party upon termination. Yorkville Securities LLC continues as a sales agent under the separate Equity Distribution Agreement dated December 29, 2025. Medicus Pharma Ltd. operates in the pharmaceutical industry.

On September 4, 2026, Medicus Pharma Ltd. issued an aggregate of 8,529,412 restricted common shares to certain officers and employees in lieu of cash bonuses totaling approximately $1.45 million. The share count was calculated by dividing the bonus amounts by the closing price of $0.1705 per share on September 3, 2026. No additional consideration was paid or received by the company for this issuance, which was exempt from registration under Section 4(a)(2) of the Securities Act of 1933 as a private transaction not involving a public offering. Medicus Pharma Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of drug products.